UY37981A - Novedosos antagonistas del receptor b2 de bradiquinina - Google Patents

Novedosos antagonistas del receptor b2 de bradiquinina

Info

Publication number
UY37981A
UY37981A UY0001037981A UY37981A UY37981A UY 37981 A UY37981 A UY 37981A UY 0001037981 A UY0001037981 A UY 0001037981A UY 37981 A UY37981 A UY 37981A UY 37981 A UY37981 A UY 37981A
Authority
UY
Uruguay
Prior art keywords
bradiquinine
new
compound
receiver antagonists
antagonists
Prior art date
Application number
UY0001037981A
Other languages
English (en)
Inventor
Christoph Gibson
Joern Saupe
Ambrosi Horst-Dieter
Ole Haustedt Lars
Original Assignee
Pharvaris B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharvaris B V filed Critical Pharvaris B V
Publication of UY37981A publication Critical patent/UY37981A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a un compuesto de acuerdo con la formula general (I), que actúa como un antagonista del receptor de bradiquinina (BK) B2; a una composición farmacéutica que contiene uno o más compuestos de la invención; a una preparación de combinación que contiene al menos un compuesto de la invención y al menos otro principio farmacéuticamente activo adicional; y a los usos de dicho(s) compuesto(s), incluido el uso como medicamento.
UY0001037981A 2017-11-24 2018-11-23 Novedosos antagonistas del receptor b2 de bradiquinina UY37981A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17203675 2017-11-24

Publications (1)

Publication Number Publication Date
UY37981A true UY37981A (es) 2019-06-28

Family

ID=60473364

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037981A UY37981A (es) 2017-11-24 2018-11-23 Novedosos antagonistas del receptor b2 de bradiquinina

Country Status (29)

Country Link
US (3) US10836748B2 (es)
EP (2) EP3998259A1 (es)
JP (2) JP7164619B2 (es)
KR (1) KR102413321B1 (es)
CN (1) CN111433196B (es)
AR (1) AR113839A1 (es)
AU (1) AU2018371186B2 (es)
BR (1) BR112020010298A2 (es)
CA (1) CA3082948A1 (es)
CY (1) CY1125348T1 (es)
DK (1) DK3713928T3 (es)
EA (1) EA202091256A1 (es)
ES (1) ES2908409T3 (es)
HR (1) HRP20220429T1 (es)
HU (1) HUE058217T2 (es)
IL (1) IL274883B2 (es)
LT (1) LT3713928T (es)
MA (1) MA50804B1 (es)
MX (1) MX2020005287A (es)
NZ (1) NZ764304A (es)
PH (1) PH12020550683A1 (es)
PL (1) PL3713928T3 (es)
PT (1) PT3713928T (es)
RS (1) RS63087B1 (es)
SG (1) SG11202004653TA (es)
SI (1) SI3713928T1 (es)
TW (1) TWI768156B (es)
UY (1) UY37981A (es)
WO (1) WO2019101906A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019101906A1 (en) 2017-11-24 2019-05-31 Pharvaris B.V. Novel bradykinin b2 receptor antagonists
UY38707A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
AR118982A1 (es) * 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
EP4243824A1 (en) 2020-11-12 2023-09-20 Pharvaris GmbH Prophylaxis and treatment of angioedema
WO2023012324A1 (en) 2021-08-05 2023-02-09 Pharvaris Gmbh Solid form of a bradykinin b2-receptor antagonist
AU2022323749A1 (en) 2021-08-05 2024-02-08 Pharvaris Gmbh Lipid-based composition for oral administration of bradykinin b2-receptor antagonists
WO2023180577A1 (en) 2022-03-25 2023-09-28 Pharvaris Gmbh Therapeutic uses of bradykinin b2-receptor antagonists
WO2023180575A1 (en) 2022-03-25 2023-09-28 Pharvaris Gmbh Solid composition comprising solubilised bradykinin b2-receptor antagonists
TW202345810A (zh) 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽b2受體拮抗劑之固態延長釋放組成物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
DE69533174T2 (de) 1994-10-27 2004-11-18 Fujisawa Pharmaceutical Co., Ltd. Pyridopyrimidinone, chinoline und anellierte n-heterozyklen als bradykinin-antagonisten
FR2737892B1 (fr) 1995-08-17 1997-10-24 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique
GB9602029D0 (en) 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
DE19609827A1 (de) 1996-03-13 1997-09-18 Hoechst Ag Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten
DE19610784A1 (de) 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19612067A1 (de) 1996-03-27 1997-10-02 Hoechst Ag Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen
AUPN952696A0 (en) 1996-04-29 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
WO1999064039A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Bradykinin antagonists
HUP0104110A3 (en) 1998-10-21 2003-01-28 Astellas Pharma Inc Chuo Ku Vitreous form of known bradykinin antagonist and medicament containing it
FR2790260B1 (fr) 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
GB9913079D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
AU2001229580A1 (en) 2000-01-18 2001-08-14 Nuerogen Corporation Substituted imidazoles as selective modulators of bradykinin b2 receptors
CA2364178C (en) 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
US6958349B2 (en) 2002-04-10 2005-10-25 Ortho-Mcneil Pharmaceuticals, Inc. Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
ITMI20021247A1 (it) 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
EP1741444A1 (en) 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
TWI407960B (zh) * 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽b2受體調節劑
AR073304A1 (es) * 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
RU2015138443A (ru) 2013-03-14 2017-04-20 Шир Хьюман Дженетик Терапис, Инк. Способы лечения ангионевротического отека, опосредованного рецепторами брадикинина в2
WO2019101906A1 (en) 2017-11-24 2019-05-31 Pharvaris B.V. Novel bradykinin b2 receptor antagonists

Also Published As

Publication number Publication date
CN111433196A (zh) 2020-07-17
US20220135543A1 (en) 2022-05-05
KR102413321B1 (ko) 2022-06-24
EP3713928A1 (en) 2020-09-30
US11820756B2 (en) 2023-11-21
IL274883B2 (en) 2023-11-01
IL274883A (en) 2020-07-30
CY1125348T1 (el) 2024-02-16
ES2908409T3 (es) 2022-04-29
RS63087B1 (sr) 2022-04-29
AR113839A1 (es) 2020-06-17
EP3998259A1 (en) 2022-05-18
AU2018371186B2 (en) 2022-05-12
IL274883B1 (en) 2023-07-01
PH12020550683A1 (en) 2021-03-15
US20200255405A1 (en) 2020-08-13
TWI768156B (zh) 2022-06-21
PL3713928T3 (pl) 2022-07-11
HRP20220429T1 (hr) 2022-05-27
MA50804A (fr) 2020-09-30
PT3713928T (pt) 2022-03-08
WO2019101906A1 (en) 2019-05-31
NZ764304A (en) 2024-02-23
JP7164619B2 (ja) 2022-11-01
US11261173B2 (en) 2022-03-01
KR20200094174A (ko) 2020-08-06
US20210017158A1 (en) 2021-01-21
EA202091256A1 (ru) 2020-10-05
AU2018371186A1 (en) 2020-05-28
US10836748B2 (en) 2020-11-17
TW202017916A (zh) 2020-05-16
MX2020005287A (es) 2020-08-13
DK3713928T3 (da) 2022-04-04
HUE058217T2 (hu) 2022-07-28
BR112020010298A2 (pt) 2020-11-17
LT3713928T (lt) 2022-05-10
SI3713928T1 (sl) 2022-09-30
MA50804B1 (fr) 2022-05-31
CN111433196B (zh) 2023-06-06
SG11202004653TA (en) 2020-06-29
JP2023002701A (ja) 2023-01-10
CA3082948A1 (en) 2019-05-31
EP3713928B1 (en) 2022-01-12
JP2021504464A (ja) 2021-02-15

Similar Documents

Publication Publication Date Title
UY37981A (es) Novedosos antagonistas del receptor b2 de bradiquinina
UY38707A (es) Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
CO2018002063A2 (es) Análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
CL2016002348A1 (es) Agonistas del receptor muscarínico
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
CO2017011411A2 (es) Derivados de ciclohexano sustituido con amido
PE20151437A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CO7310529A2 (es) Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano rory
CY1123479T1 (el) Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1
BR112016010383A2 (pt) compostos de pyy seletivos e usos dos mesmos
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
GT201300122A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
BR112017023147A2 (pt) azabenzimidazóis e seu uso como moduladores do receptor de ampa
CL2019003078A1 (es) Nuevos derivados de pirazol bicíclicos.
CL2018000529A1 (es) Compuestos heteroarilo y su uso como fármacos terapéuticos.
SA518390920B1 (ar) مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة
MY187614A (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
CL2017001720A1 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos.
EA202090995A1 (ru) Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1
EA202090925A1 (ru) Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1
UY38706A (es) Antagonistas cíclicos del receptor b2 de bradiquinina
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
AR107310A1 (es) Inhibidores de tetrahidrocarbazol de receptores sirt1